Immunotherapy is a preventive treatment for allergies to substances such as grass pollens, house dust mites and bee venom. Learn more through ACAAI.
Jeffrey Grass, MD, a radiation oncologist with OHC, answers some of the most common questions men ask about prostate cancer and treatment.
Looking for Immunotherapy treatment in India? Learn more about the benefits of Immunotherapy for cancer treatment, side effects.
Opener sequence created for Medscape TV program that explores the impact of Immunotherapies for lung cancer. Activated T cells are seen here targeting and destroying…
Empowered by state-of-the-art technologies and advanced platforms in the field of antibody discovery and immunotherapy, Creative Biolabs offers world-leading chimeric antigen receptor macrophage (CAR-MA) services for solid tumor treatment with academic purposes. https://www.creative-biolabs.com/car-t/one-stop-car-ma-therapy-development.htm
More patients with advanced melanoma with BRAF mutations (BRAF+) treated first with the immunotherapy drugs ipilimumab (Yervoy) and nivolumab (Opdivo) were alive after 2 years than patients treated with the targeted therapies dabrafenib (Tafinlar) and trametinib (Mekinist), according to results of the DREAMseq trial.
This article covers the top ways professionals use to measure #ImmunotherapyPotency. If you want to learn more about it, let’s explore the points discussed below. #ImmunoTherapyAssay #ChromiumReleaseAssays #LDHAssays #BioelectronicAssays #MTTAssays
Important questions to ask your allergist about starting allergy shots (immunotherapy injections) for dust mite, pollen and animal allergies.
Researchers unveiled a novel approach to combat Alzheimer’s disease by activating microglia, the brain's immune cells, to devour amyloid beta plaques, a hallmark of the condition.
Your guide to the most essential developments in life sciences.
Chemoimmunotherapy is an emerging treatment option for cancer that combines traditional chemotherapy with immunotherapy. This approach aims to increase the efficacy of cancer treatment by simultaneously targeting cancer cells through chemotherapy ...
Bispecific antibodies (BsAbs) are a new class of cancer immunotherapy drugs targeting two structures: immune cells and tumor antigens. This approach offers increased specificity, enhanced immune activation, and potential to overcome immune escape mechanisms.
Combining information from different cancer scans could offer a way to predict if immunotherapy will work, according to a small unpublished study.
Biomedical engineering researchers at North Carolina State University and the University of North Carolina at Chapel Hill have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer. In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.
Due to the expression of paternal antigens by the embryo, pregnancy is considered as a semi-allograft and so immunological dysregulation is considered as one of the important causes in repeated impla...
Several non-redundant features of the tumour microenvironment facilitate immunosuppression and limit anticancer immune responses. These include physical barriers to immune infiltration, the recruitment of suppressive immune cells and the upregulation of ligands on tumour cells that bind to inhibitory receptors on immune cells. Recent insights into the importance of the metabolic restrictions imposed by the tumour microenvironment on antitumour T cells have begun to inform immunotherapeutic anticancer strategies. Therapeutics that target metabolic restrictions, such as low glucose levels, a low pH, hypoxia and the generation of suppressive metabolites, have shown promise as combination therapies for different types of cancer. In this Review, we discuss the metabolic aspects of the antitumour T cell response in the context of immune checkpoint blockade, adoptive cell therapy and treatment with oncolytic viruses, and discuss emerging combination strategies. Immunotherapeutic approaches to cancer can be affected by metabolic restrictions that limit the potency of anticancer T cell responses. In this Review, DePeaux and Delgoffe discuss the metabolic features of the tumour microenvironment that limit anticancer immune responses, as well as emerging therapeutic approaches to target these.
It may be possible to 'retrain' the immune system to slow the progression of type 1 diabetes, according to results of a clinical trial published today in the journal Science Translational Medicine.
A new study has explored why some patients do not respond to cancer immunotherapy, demonstrating that specific gut bacteria can alter therapy responses and immune signaling in mouse models.
Immunotherapy is an exciting new treatment option for advanced lung cancer. But it doesn’t work for everyone. Learn how to stop the warning signs of treatment failure.
Chemical compound extends survival by months, in mice
